Cytokinetics - Stock Price History | CYTK

Historical daily share price chart and data for Cytokinetics since 2021 adjusted for splits. The latest closing stock price for Cytokinetics as of September 24, 2021 is 33.13.
  • The all-time high Cytokinetics stock closing price was 105.40 on May 05, 2004.
  • The Cytokinetics 52-week high stock price is 34.45, which is 4% above the current share price.
  • The Cytokinetics 52-week low stock price is 14.71, which is 55.6% below the current share price.
  • The average Cytokinetics stock price for the last 52 weeks is 22.96.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Cytokinetics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 18.3362 10.5500 28.9600 8.7500 20.7800 95.85%
2019 9.9868 6.8200 14.2500 5.9500 10.6100 67.88%
2018 8.0609 8.7500 10.0500 5.9100 6.3200 -22.45%
2017 12.6532 12.4000 17.0000 7.2500 8.1500 -32.92%
2016 9.1569 10.0000 12.5500 6.1700 12.1500 16.16%
2015 7.6714 7.3700 12.9500 5.5100 10.4600 30.59%
2014 5.8718 6.7200 12.9900 3.0700 8.0100 23.23%
2013 7.8704 4.0204 13.8200 4.0204 6.5000 64.17%
2012 5.1871 5.8788 7.2585 3.5993 3.9592 -31.25%
2011 7.9684 12.9574 12.9574 5.7588 5.7588 -54.07%
2010 16.4334 18.6563 21.3557 12.2675 12.5375 -28.18%
2009 16.9971 17.0966 31.7936 8.6983 17.4565 2.11%
2008 21.8828 27.2945 34.1332 11.9976 17.0966 -39.75%
2007 37.0864 50.0300 51.5897 26.3947 28.3743 -36.76%
2006 41.3366 37.6125 47.9304 31.6737 44.8710 14.37%
2005 46.5644 58.8482 61.0078 29.2741 39.2322 -36.20%
2004 68.3886 97.5405 105.3989 45.1110 61.4877 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.807B $0.056B
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71